These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15220742)

  • 1. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report.
    Chen HT; Chen KH; Hsu WM
    Cornea; 2004 Jul; 23(5):527-9. PubMed ID: 15220742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical anesthetic abuse keratopathy: a commonly overlooked health care problem.
    Yagci A; Bozkurt B; Egrilmez S; Palamar M; Ozturk BT; Pekel H
    Cornea; 2011 May; 30(5):571-5. PubMed ID: 21598429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Particularly rapid appearance of a severe toxic keratopathy caused by oxybuprocaine].
    Jallet G; Cleirens S; Girard E; Béchetoille A
    Bull Soc Ophtalmol Fr; 1980; 80(4-5):385-7. PubMed ID: 7460172
    [No Abstract]   [Full Text] [Related]  

  • 4. Topical anesthesia-induced keratopathy after laser-assisted subepithelial keratectomy.
    Rao SK; Wong VW; Cheng AC; Lam PT; Lam DS
    J Cataract Refract Surg; 2007 Aug; 33(8):1482-4. PubMed ID: 17662448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corneal thickness values before and after oxybuprocaine 0.4% eye drops.
    Asensio I; Rahhal SM; Alonso L; Palanca-Sanfrancisco JM; Sanchis-Gimeno JA
    Cornea; 2003 Aug; 22(6):527-32. PubMed ID: 12883345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxybuprocaine keratopathy: a preventable disease.
    Penna EP; Tabbara KF
    Br J Ophthalmol; 1986 Mar; 70(3):202-4. PubMed ID: 3954977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degree and duration of corneal anesthesia after topical application of 0.4% oxybuprocaine hydrochloride ophthalmic solution in ophthalmically normal dogs.
    Douet JY; Michel J; Regnier A
    Am J Vet Res; 2013 Oct; 74(10):1321-6. PubMed ID: 24066916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinous Anterior Uveitis Following Topical Tetracaine Abuse.
    Makri OE; Plotas P; Tsapardoni F; Georgalas I; Georgakopoulos CD
    Curr Drug Saf; 2017; 12(3):216-218. PubMed ID: 28521706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrastructural alterations in the endothelium in a patient with topical anesthetic abuse keratopathy.
    Risco JM; Millar LC
    Ophthalmology; 1992 Apr; 99(4):628-33. PubMed ID: 1584582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical diclofenac sodium in the management of anesthetic abuse keratopathy.
    Dornic DI; Thomas JM; Lass JH
    Am J Ophthalmol; 1998 May; 125(5):719-21. PubMed ID: 9625565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corneal thickness differences between sexes after oxybuprocaine eye drops.
    Fernandez-Garcia P; Cerviño A; Quiles-Guiñau L; Albarran-Diego C; Garcia-Lazaro S; Sanchis-Gimeno JA
    Optom Vis Sci; 2015 Jan; 92(1):89-94. PubMed ID: 25360701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal anesthetic abuse and Candida keratitis.
    Chern KC; Meisler DM; Wilhelmus KR; Jones DB; Stern GA; Lowder CY
    Ophthalmology; 1996 Jan; 103(1):37-40. PubMed ID: 8628558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epitheliopathy from a single application of preservative free oxybuprocaine (0.4%) in a patient with Sjogren's syndrome.
    Ansari H; Weinberg L; Spencer N
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24038291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.
    Georgakopoulos CD; Vasilakis P; Makri OE; Beredima E; Pharmakakis N
    Cutan Ocul Toxicol; 2011 Dec; 30(4):320-2. PubMed ID: 21517719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical anesthetic eye drops abuse: are we aware of the danger?
    Erdem E; Undar IH; Esen E; Yar K; Yagmur M; Ersoz R
    Cutan Ocul Toxicol; 2013 Sep; 32(3):189-93. PubMed ID: 23410261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent corneal ulceration as late complication of toxic keratitis.
    Wasserman BN; Liss RP; Santander SH
    Br J Ophthalmol; 2002 Feb; 86(2):245-6. PubMed ID: 11815357
    [No Abstract]   [Full Text] [Related]  

  • 17. Keratopathy due to ophthalmic drug abuse with corneal melting and perforation presenting as Mooren-like ulcer: A case report.
    Wu H; Hu Y; Shi XR; Xu F; Jiang CY; Huang R; Jia H
    Exp Ther Med; 2016 Jul; 12(1):343-346. PubMed ID: 27347060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical ocular anesthetic abuse: case report.
    Sun MH; Huang SC; Chen TL; Tsai RJ
    Chang Gung Med J; 2000 Jun; 23(6):377-81. PubMed ID: 10958042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anesthetic eye drop instillation on the distribution of corneal thickness.
    Sanchis-Gimeno JA; Palanca-Sanfrancisco JM; García-Lázaro S; Madrid-Costa D; Cerviño A
    Cornea; 2013 May; 32(5):e102-5. PubMed ID: 23172120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical findings in patients with topical anaesthetic abuse keratitis: a report of five cases.
    Katsimpris JM; Sarantoulakou M; Kordelou A; Petkou D; Petropoulos IK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):303-8. PubMed ID: 17458798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.